Based on a highly innovative therapeutic concept ProFem develops new medicines for gynecological diseases which are characterized by a hitherto unmet medical need and high market potential. ProFem’s activities are currently focused on infectious diseases of the female lower genitourinary tract associated with the growth of biofilms.
VelaLabs services as a GLP and GMP certified and G(C)LP compliant contract laboratory cover analytical services for Biologics (ATMPs, Biopharmaceuticals, Originator products, Biosimilar Candidates, Biosimilars, Blood and blood components, Vaccines), Chemicals and Excipients from early stages of product development (non-clinical, clinical) until market release testing for Pharma and Biotech companies as well as storage facilities enabling long term stability studies.
Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
GENSPEED Biotech GmbH was founded in October 2016 as a spin-off of Greiner Bio-One. We develop, produce and distribute rapid tests based on the IVD-CE certified GENSPEED® technology. With a novel combination of microfluidics, miniaturized optical detection and automation, GENSPEED® allows for the first time to detect a multiple of parameters simultaneously and with high sensitivity at the point of care (POC) in just a few minutes.
Allcyte is a pioneer in the field of functional precision oncology. The company provides actionable data on the activity of drug candidates directly in live tissue samples of human cancer patients to support strategic R
Technology transfer, pharmaceutical development for solid dosage forms (tablet, granulates, a.o.) for clinical studies, liquids and creams. Study development and monitoring (Phase I-II), CRO biomarker development for inflammatory and autoimmun diseases, product management for pharmacies, licensing and marketing
Please visit our website: www.oncoone.com
Pfizer Manufacturing Austria is Pfizer’s production site at Orth an der Donau. The plant meets global demand for vaccines to protect against tickborne encephalitis and meningitis caused by serogroup C meningococci.
Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase where it is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete and selective elimi
APEIRON Biologics AG at a glance: APEIRON Biologics is a privately held European biotech company based in Vienna, Austria, focused on the discovery and development of treatments for respiratory diseases and novel cancer immunotherapies. APEIRON Biologics´ projects and technologies are based on a strong patent portfolio and partnerships with leading pharmaceutical companies and academic institutions.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.
a:head aims to develop new therapeutics for the treatment of brain disorders based on human cerebral organoids
Origimm (‘Origins of immunity’) is a biotech company that specializes in the discovery of antigens and dermatological drug targets. The company uses its proprietary technology that employs reverse functional screening to discover and develop breakthrough therapies for the prevention and treatment of skin microbiome-associated diseases such as acne vulgaris and other microbiome-associated infections.
What if we could give the body instructions to produce its own drugs? This would be nothing less than a new era in drug therapy and is exactly what messenger RNA (mRNA) could achieve. At ACCANIS, we develop innovative therapeutics for the treatment of common, localized diseases using mRNA. Each cell in your body uses mRNA to translate genetic information into proteins. ACCANIS´ innovative technology takes advantage of this natural mechanism in order to enable effective, on-demand therapeutics.
Solgate is a new research-driven biopharmaceutical startup that develops drugs targeting solute carrier (SLC) proteins, the largest family of membrane transporters. By modulating the function of the “gates” to cellular metabolism, Solgate aims to address unmet medical needs in neurological diseases, in metabolic disorders and in cancer. Solgate is located in the newly established IST Park, a space housing a growing community of technology startups and biotech companies, adjacent to IST Austria.